We are live on ! Find out more
VA

VR Adviser Portfolio holdings

AUM $2.68B
1-Year Est. Return 422.73%
This Fund
S&P 500
This Quarter Est. Return
-13.87%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$1.46B
AUM Growth
-$452M
Cap. Flow
-$46.2M
Cap. Flow %
-3.17%
Top 10 Hldgs %
70.47%
Holding
41
New
3
Increased
5
Reduced
10
Closed
4

Top Buys

Rank Stock Value
1
UPB
Upstream Bio Inc
UPB
+$51.3M
2
PRAX icon
Praxis Precision Medicines
PRAX
+$20.5M
3
CDTX
Cidara Therapeutics
CDTX
+$12.4M
4
ENGN icon
enGene Therapeutics
ENGN
+$11.5M
5
ORKA
Oruka Therapeutics
ORKA
+$4.88M

Top Sells

Rank Stock Value
1
EWTX icon
Edgewise Therapeutics
EWTX
+$26.7M
2
TERN
Terns Pharmaceuticals
TERN
+$15.8M
3
MRUS
Merus
MRUS
+$15.2M
4
AQST icon
Aquestive Therapeutics
AQST
+$13.5M
5
TSHA icon
Taysha Gene Therapies
TSHA
+$12M

Sector Composition

Rank Sector Weight
1 Healthcare 99.48%
2 Financials 0.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APGE icon
1
Apogee Therapeutics
APGE
$10.1B
$385M 26.4%
8,493,321
– –
OCUL icon
2
Ocular Therapeutix
OCUL
$1.79B
$109M 7.48%
12,762,462
– –
ELVN icon
3
Enliven Therapeutics
ELVN
$3.92B
$90.6M 6.22%
4,026,331
– –
PRAX icon
4
Praxis Precision Medicines
PRAX
$8.58B
$76.2M 5.23%
989,985
+283,854
+40% +$20.5M
VRDN icon
5
Viridian Therapeutics
VRDN
$2.09B
$74.4M 5.11%
3,882,709
– –
ORKA
6
Oruka Therapeutics
ORKA
$5.82B
$63.7M 4.37%
3,285,620
+200,000
+6% +$4.88M
SYRE icon
7
Spyre Therapeutics
SYRE
$8.54B
$62.5M 4.29%
2,685,448
– –
PHVS icon
8
Pharvaris
PHVS
$2.28B
$61.7M 4.24%
3,220,130
-175,476
-5% -$3.61M
KALV
9
DELISTED
KalVista Pharmaceuticals
KALV
$52.9M 3.63%
6,249,731
– –
DYN icon
10
Dyne Therapeutics
DYN
$4.7B
$51.2M 3.51%
2,173,913
– –
COGT icon
11
Cogent Biosciences
COGT
$6.65B
$44.3M 3.04%
5,684,411
+244
+0% +$2.43K
ERAS icon
12
Erasca
ERAS
$6.3B
$40.7M 2.79%
16,216,216
– –
DNTH icon
13
Dianthus Therapeutics
DNTH
$5.84B
$38M 2.61%
1,744,373
– –
UPB
14
Upstream Bio Inc
UPB
$343M
$37.7M 2.59%
+2,295,319
New +$51.3M
ORIC icon
15
Oric Pharmaceuticals
ORIC
$1.15B
$35.5M 2.43%
4,394,527
– –
ENGN icon
16
enGene Therapeutics
ENGN
$120M
$33.6M 2.3%
5,046,414
+1,480,573
+42% +$11.5M
MRUS
17
DELISTED
Merus
MRUS
$24.9M 1.71%
592,411
-315,552
-35% -$15.2M
ATXS
18
DELISTED
Astria Therapeutics
ATXS
$22M 1.51%
2,457,348
-1,001,297
-29% -$10.6M
CDTX
19
DELISTED
Cidara Therapeutics
CDTX
$20.6M 1.41%
+765,723
New +$12.4M
CGEM icon
20
Cullinan Oncology
CGEM
$1.01B
$16.8M 1.15%
1,379,965
– –
FDMT icon
21
4D Molecular Therapeutics
FDMT
$532M
$16.4M 1.13%
2,952,371
-1,447,629
-33% -$11.4M
ARTV
22
Artiva Biotherapeutics
ARTV
$491M
$16.2M 1.11%
1,609,569
– –
MRSN
23
DELISTED
Mersana Therapeutics
MRSN
$14.7M 1.01%
410,312
-42,808
-9% -$2.21M
ABVX
24
Abivax
ABVX
$10.9B
$9.85M 0.68%
1,345,780
– –
AQST icon
25
Aquestive Therapeutics
AQST
$463M
$9.36M 0.64%
2,629,786
-2,925,769
-53% -$13.5M
1
2

Similar funds

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
WGI
Westwood Global Investments Boston, Massachusetts $2.68B AUM 76.4% 1-Year Est. Return
TCAM
Turtle Creek Asset Management Toronto, Ontario, Canada $2.67B AUM 0.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
HC
Henshaw Capital Woburn, Massachusetts $2.7B AUM 29.67% 1-Year Est. Return
CI
Capital International Los Angeles, California $2.7B AUM 31.08% 1-Year Est. Return
PCA
Pallas Capital Advisors Braintree, Massachusetts $2.66B AUM 22.31% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

VR Adviser's Q4 2024 Portfolio in Review

As of Q4 2024, VR Adviser held 41 positions worth $1.46B, down 24% from $1.91B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

VR Adviser withdrew a net $46.2M in Q4 2024, closing 4 positions and reducing 10 holdings. Its most notable exit was Edgewise Therapeutics, an estimated $26.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

Against the trend, VR Adviser opened a new position in Upstream Bio Inc worth $37.7M.

  • VR Adviser's largest Q4 2024 buy was Upstream Bio Inc: 2,295,319 shares worth $37.7M.
  • VR Adviser added most to Praxis Precision Medicines in Q4 2024, an estimated $20.5M increase.
  • VR Adviser's biggest Q4 2024 reduction was Terns Pharmaceuticals, cutting an estimated $15.8M.
  • VR Adviser fully exited Edgewise Therapeutics in Q4 2024, selling an estimated $26.7M.
  • VR Adviser's ten largest holdings make up 70% of its $1.46B portfolio in Q4 2024.
  • VR Adviser opened 3 new positions and closed 4 in Q4 2024.
  • VR Adviser's portfolio value fell 24% quarter-over-quarter to $1.46B.

Based on VR Adviser's 13F filing for Q4 2024, filed 14 Feb 2025.